Is this you? Create Your Porfile
Avatar

Swen Hoelder

Aventis Pharma

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Swen Hoelder is active.

Explore More

Publication

Featured researches published by Swen Hoelder.

Archive | 2003

Pyridazinone derivatives as gsk-3beta inhibitors

Swen Hoelder; Thorsten Naumann; Karl Schoenafinger; David William Will; Hans Matter; Guenter Mueller; Suisse Dominique Le; Bernard Baudoin; Thomas Rooney; Franck Halley; Gilles Tiraboschi

Archive | 2006

4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS

Karl Schoenafinger; Swen Hoelder; David William Will; Hans Matter; Guenther Mueller; Martin Bossart

Archive | 2003

Pyridazinone derivatives as cdk2-inhibitors

Swen Hoelder; Thorsten Naumann; Karl Schoenafinger; David William Will; Hans Matter; Guenter Mueller; Suisse Dominique Le; Bernard Baudoin; Thomas Rooney; Franck Halley; Gilles Tiraboschi; Cécile Combeau; Ingrid Sassoon; Anke Steinmetz

Archive | 2001

Substituted and unsubstituted benzooxathiazoles and compounds derived therefrom

Stefan Petry; Karl-Heinz Baringhaus; Swen Hoelder; Guenther Mueller

Archive | 2005

Novel 4-benzimidazol-2-ylpyridazin-3-one derivatives

Swen Hoelder; Karl Schoenafinger; David William Will; Hans Matter; Günter Müller; Cécile Combeau; Christine Delaisi; Anke Steinmetz; Ingrid Sassoon

Archive | 2002

New 4-(carboxamido or acylamino)-6-(hetero)aryl-pyridazinone derivatives are tau-protein phosphorylation inhibitors useful e.g. for treating neurodegenerative diseases, diabetes, hypertension or cancer

Dominique Lesuisse; Franck Halley; Bernard Baudoin; Thomas Rooney; Swen Hoelder; Thorsten Naumann; Gilles Tiraboschi

Archive | 2005

Novel pyridazinone derivatives as inhibitors of cdk2

Swen Hoelder; Guenter Mueller; Karl Schoenafinger; David William Will; Hans Matter; Bossart; Cécile Combeau; Christine Delaisi; Sassoon; Anke Steinmetz; Didier. Bernard

Archive | 2009

Pyridazinone kinase inhibitors

Swen Hoelder; Günter Müller; Karl Schoenafinger; David William Will; Hans Matter; Martin Bossart; Cécile Combeau; Christine Delaisi; Ingrid Sassoon; Anke Steinmetz; Didier Benard

Archive | 2009

Novel Pyridazinone Derivatives

Swen Hoelder; Günter Müller; Karl Schoenafinger; David William Will; Hans Matter; Martin Bossart; Cécile Combeau; Christine Delaisi; Ingrid Sassoon; Anke Steinmetz; Didier Benard

Archive | 2006

4-benzimidazol-2-ylpyridazin-3-one derivatives

Swen Hoelder; Karl Schoenafinger; David William Will; Hans Matter; Günter Müller; Cécile Combeau; Christine Delaisi; Anke Steinmetz; Ingrid Sassoon

Explore More

Collaboration

Dive into the Swen Hoelder's collaboration.

Top Co-Authors
Avatar

Karl Schoenafinger

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

David William Will

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Guenter Mueller

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Anke Steinmetz

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Cécile Combeau

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Ingrid Sassoon

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Bernard Baudoin

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Franck Halley

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Gilles Tiraboschi

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Guenther Mueller

Aventis Pharma

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge